Article title: Improvement in clinical disease activity index when treatment selection is informed by the
tumor necrosis factor-ɑ inhibitor molecular signature response classifier: analysis from the study to accelerate information of molecular signatures in rheumatoid arthritisAuthors: Strand, V., Zhang, L., Arnaud, A., Connolly-Strong, E., Asgarian, S. & Withers, J. B.
Journal: EXPERT OPINION ON BIOLOGICAL THERAPY
DOI: https://doi.org/10.1080/14712598.2022.2066972
When this article was first published, there were some errors in Table 1. The following changes have been made to correct these:
In column PNR-altMOA, row Duration of disease (years), median (IQR; n), the Q3 value has been changed from 0.5 to 10.5.
In column NPNR-altMOA, row Duration of disease (years), median (IQR; n), the Q3 value has been changed from 6.65 to 16.65, and the IQR has been updated from 14.4 to 14.45.
In column NPNR-altMOA, row Female, n (%), the value has been changed n=54 (7) to n=54 (77).
In column P-value (NPNR-TNFi vs. NPNR-altMOA), for rows White, Black or African American, American Indian or Alaskan Native, and Hydroxychloroquine, n, (%), zeros were added to maintain a consistent number of significant digits.
In column NPNR-TNFi, row Age (year), mean (SD), a zero was added to the SD value to maintain consistency.
In columns PNR-TNFi through NPNR-altMOA, row Duration of disease (years), median (IQR: n), all values now display two significant digits. With the exception of the PNR-altMOA IQR value, which was changed from 8.2 to 8.25, zeros were added to all other values.
In columns PNR-TNFi through NPNR-altMOA, row HAQ at baseline, mean (SD), the standard deviation values have been corrected by adding a decimal point in front of each digit (eg., changed from 6 to 0.6)
Errors in row alignment have also been corrected as follows:
The values in the columns P-value (PNR-TNFi vs. PNR-altMOA) and P-value (NPNR-TNFi vs. NPNR-altMOA) for rows N through to Duration of disease (years), median (IQR; n) have been shifted down one row, leaving these columns blank for row N, and replacing the values in row Race, n (%).
The values in columns PNR-TNFi, PNR-altMOA, NPNR-TNFi, NPNR-altMOA, P-value (PNR-TNFi vs. PNR-altMOA) and P-value (NPNR-TNFi vs. NPNR-altMOA) for rows Race, n (%) through to RF positive, n (%), have been shifted down one row, leaving the first four of these columns blank for row Race, n (%), and replacing the data in the row CCP positive, n (%) which was erroneously a copy of the row Age (year), Mean (SD).
Data in the row Hydroxychloroquine, n (%), which was erroneously a copy of the CRP at baseline, mg/dl data has now been provided.
The values in columns PNR-TNFi and NPNR-TNFi for rows Adalimumab through Infliximab have been shifted up one row and replacing the data in the Etanercept which was erroneously a copy of the row TNFi, n (%).
Additionally, there were two edits to a sentence found in Patients and methods, Section 2.1. AIMS patient cohort that originally read as CDAI ≥ 10 and the word ‘following’ was changed to the word ‘and’.
The corrected statement reads: “Eligibility criteria for analysis were the following: age ≥ 18 years, a clinical diagnosis of RA treated by a rheumatologist, b/tsDMARD-naïve or TNFi-exposed at time of MSRC testing with moderate-to-severe disease at baseline according to CDAI > 10, patients to have made a b/tsDMARD treatment decision and MSRC testing, and data to calculate CDAI were available at baseline and at least one follow-up visit.”
These changes are not considered to impact the conclusions of the article.
Table 1. Patient demographics and baseline characteristics.